NEWS HIGHLIGHTS RELATED TO BONIVA INJECTION
Media Articles Related to Boniva Injection (Ibandronic Acid)
NPS Pharma says Glaxo stops osteoporosis drug study (Reuters) Source: Y! Health Osteoporosis News [2008.09.25]
Long-Term Osteoporosis Risk in Men Rises with Weight Loss Source: MedPage Today Endocrinology [2008.09.19]
ACP Issues Treatment Guideline for Osteoporosis Source: MedPage Today Endocrinology [2008.09.17]
New Merck osteoporosis drug boosts bone density (AP) Source: Y! Health Osteoporosis News [2008.09.16]
Most Women With Osteoporosis Unaware of Raised Fracture Risk Source: MedicineNet Fracture Specialty [2008.09.16]
Published Studies Related to Boniva Injection (Ibandronic Acid)
Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. [2006]
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). [2005.12]
Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. [2008.05.27]
Eletriptan: a review of its use in the acute treatment of migraine. [2006]
Oral ibandronic acid. [2005.02]
Clinical Trials Related to Boniva Injection (Ibandronic Acid)
BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy. [Active, not recruiting]
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva [Completed]
BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis [Active, not recruiting]
SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis. [Active, not recruiting]
A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis. [Active, not recruiting]
|